Emily Gibbons, Gilead Sciences: the lenacapavir partnership

Emily Gibbons, Gilead Sciences, explains the partnership between Gilead Sciences, the Trump administration, and the Global Fund to bring lenacapavir, the twice-yearly injectable HIV/AIDS prevention tool, to two million persons at-risk in ten African countries in three years.